Shire Finds Another Orphan Opportunity, Licenses Acceleron's DMD Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
The deal gives the Irish pharma rights outside the U.S. and Canada to an entire family of proteins that address muscle disorders.
You may also be interested in...
Amgen, Kleiner Perkins Spin-Out Atara Sails Into The Spotlight
Launched in fall 2012 via a partnership between Amgen and Kleiner Perkins Caufield & Byers, the Bay Area biotech has three subsidiary companies housing six biologic assets that used to belong to Amgen. With two financing rounds this year totaling $58.5 million, three candidates are slated to enter the clinic by 2015.
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications.
GSK Takes Rare Diseases Option from Prosensa
GlaxoSmithKline's tie-up with Dutch biotech Prosensa around four RNA-modulating therapeutics for Duchenne Muscular Dystrophy, a rare genetic disorder, provides recent evidence that even the largest Big Pharma are embracing the most niche of specialist disease indications.